Diagnosis and Treatment > Signs and Symptoms > Renal cyst

You are looking at 1 - 2 of 2 items

C E Stiles Department of Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, UK

Search for other papers by C E Stiles in
Google Scholar
PubMed
Close
,
R Thuraisingham Department of Nephrology, Barts Health NHS Trust, London, UK

Search for other papers by R Thuraisingham in
Google Scholar
PubMed
Close
,
D Bockenhauer UCL centre for Nephrology and Great Ormond Street Hospital NHS Trust, London, UK

Search for other papers by D Bockenhauer in
Google Scholar
PubMed
Close
,
L Platts North East Thames Regional Genetics Laboratory, Great Ormond Street Hospital NHS Trust, London, UK

Search for other papers by L Platts in
Google Scholar
PubMed
Close
,
A V Kumar North East Thames Regional Genetics Service, Great Ormond Street Hospital NHS Trust, London, UK

Search for other papers by A V Kumar in
Google Scholar
PubMed
Close
, and
M Korbonits Department of Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, UK

Search for other papers by M Korbonits in
Google Scholar
PubMed
Close

Summary

29-year-old female presenting with an 8-year history of unexplained hypomagnesaemia, which was severe enough to warrant intermittent inpatient admission for intravenous magnesium. Urinary magnesium was inappropriately normal in the context of hypomagnesaemia indicating magnesium wasting. Ultrasound imaging demonstrated unilateral renal cysts and computed tomography of kidneys, ureters and bladder showed a bicornuate uterus. Referral to genetic services and subsequent testing revealed a de novo HNF1B deletion.

Learning points:

  • HNF1B loss-of-function mutations are one of the most common monogenic causes of congenital anomalies of the kidney and urinary tract.

  • Those with HNF1B mutations may have some of a constellation of features (renal and hepatic cysts, deranged liver function tests, maturity onset diabetes of the young type 5 (MODY5), bicornuate uterus, hyperparathyroidism, hyperuricaemic gout, but presenting features are highly heterogeneous amongst patients and no genotype/phenotype correlation exists.

  • HNF1B mutations are inherited in an autosomal dominant pattern but up to 50% of cases are de novo.

  • HNF1B mutations can be part of the Chr17q12 deletion syndrome, a contiguous gene deletion syndrome.

  • Inorganic oral magnesium replacements are generally poorly tolerated with side effects of diarrhoea. Organic magnesium compounds, such as magnesium aspartate, are better absorbed oral replacement therapies.

Open access
Elena Carrillo Endocrinologists in Complejo Hospitalario Universitario de Albacete, Castilla La Mancha, Spain

Search for other papers by Elena Carrillo in
Google Scholar
PubMed
Close
,
Amparo Lomas Endocrinologists in Complejo Hospitalario Universitario de Albacete, Castilla La Mancha, Spain

Search for other papers by Amparo Lomas in
Google Scholar
PubMed
Close
,
Pedro J Pinés Endocrinologists in Complejo Hospitalario Universitario de Albacete, Castilla La Mancha, Spain

Search for other papers by Pedro J Pinés in
Google Scholar
PubMed
Close
, and
Cristina Lamas Endocrinologists in Complejo Hospitalario Universitario de Albacete, Castilla La Mancha, Spain

Search for other papers by Cristina Lamas in
Google Scholar
PubMed
Close

Summary

Mutations in hepatocyte nuclear factor 1β gene (HNF1B) are responsible for a multisystemic syndrome where monogenic diabetes (classically known as MODY 5) and renal anomalies, mostly cysts, are the most characteristic findings. Urogenital malformations, altered liver function tests, hypomagnesemia or hyperuricemia and gout are also part of the syndrome. Diabetes in these patients usually requires early insulinization. We present the case of a young non-obese male patient with a personal history of renal multicystic dysplasia and a debut of diabetes during adolescence with simple hyperglycemia, negative pancreatic autoimmunity and detectable C-peptide levels. He also presented epididymal and seminal vesicle cysts, hypertransaminasemia, hyperuricemia and low magnesium levels. In the light of these facts we considered the possibility of a HNF1B mutation. The sequencing study of this gene confirmed a heterozygous mutation leading to a truncated and less functional protein. Genetic studies of his relatives were negative; consequently, it was classified as a de novo mutation. In particular, our patient maintained good control of his diabetes on oral antidiabetic agents for a long period of time. He eventually needed insulinization although oral therapy was continued alongside, allowing reduction of prandial insulin requirements. The real prevalence of mutations in HNF1B is probably underestimated owing to a wide phenotypical variability. As endocrinologists, we should consider this possibility in young non-obese diabetic patients with a history of chronic non-diabetic nephropathy, especially in the presence of some of the other characteristic manifestations.

Learning points:

  • HNF1B mutations are a rare cause of monogenic diabetes, often being a part of a multisystemic syndrome.

  • The combination of young-onset diabetes and genitourinary anomalies with slowly progressive nephropathy of non-diabetic origin in non-obese subjects should rise the suspicion of such occurrence. A family history may not be present.

  • Once diagnosis is made, treatment of diabetes with oral agents is worth trying, since the response can be sustained for a longer period than the one usually described. Oral treatment can help postpone insulinization and, once this is necessary, can help reduce the required doses.

Open access